This is a preview of subscription content, access via your institution
Subscribe to Journal
Get full journal access for 1 year
only $9.92 per issue
All prices are NET prices.
VAT will be added later in the checkout.
Tax calculation will be finalised during checkout.
Get time limited or full article access on ReadCube.
All prices are NET prices.
The data that support the findings of this study are available from the Research Patient Data Registry at Mass General Brigham, but restrictions apply as they were used under license for the current study, and so are not publicly available. Data are however available from the authors upon reasonable request and with permission from Mass General Brigham.
Swerdlow SH, Campo E, Pileri SA, Harris NL, Stein H, Siebert R, et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood. 2016;127:2375–90. https://doi.org/10.1182/blood-2016-01-643569.
Bal S, Costa LJ, Sauter C, Litovich C, Hamadani M. Outcomes of autologous hematopoietic cell transplantation in diffuse large B cell lymphoma refractory to firstline chemoimmunotherapy. Transpl Cell Ther. 2021;27:55 e51–55 e57. https://doi.org/10.1016/j.bbmt.2020.09.004.
Maude SL, Frey N, Shaw PA, Aplenc R, Barrett DM, Bunin NJ, et al. Chimeric antigen receptor T cells for sustained remissions in leukemia. N Engl J Med. 2014;371:1507–17. https://doi.org/10.1056/NEJMoa1407222.
Schuster SJ, Svoboda J, Chong EA, Nasta SD, Mato AR, Anak O, et al. Chimeric antigen receptor T cells in refractory B-cell lymphomas. N Engl J Med. 2017;377:2545–54. https://doi.org/10.1056/NEJMoa1708566.
Schuster SJ, Bishop MR, Tam CS, Waller EK, Borchmann P, McGuirk JP, et al. Primary analysis of Juliet: a global, pivotal, phase 2 trial of CTL019 in adult patients with relapsed or refractory diffuse large B-cell lymphoma. Blood. 2017;130:577. https://doi.org/10.1182/blood.V130.Suppl_1.577.577.
Gupta S, Seethapathy H, Strohbehn IA, Frigault MJ, O’Donnell EK, Jacobson CA, et al. Acute kidney injury and electrolyte abnormalities after chimeric antigen receptor T-cell (CAR-T) therapy for diffuse large B-cell lymphoma. Am J Kidney Dis. 2020;76:63–71. https://doi.org/10.1053/j.ajkd.2019.10.011.
Gutgarts V, Jain T, Zheng J, Maloy MA, Ruiz JD, Pennisi M, et al. Acute kidney injury after CAR-T cell therapy: low incidence and rapid recovery. Biol Blood Marrow Transplant. 2020;26:1071–6. https://doi.org/10.1016/j.bbmt.2020.02.012.
Hingorani S. Renal complications of hematopoietic-cell transplantation. N Engl J Med. 2016;374:2256–67. https://doi.org/10.1056/NEJMra1404711.
Lee DW, Santomasso BD, Locke FL, Ghobadi A, Turtle CJ, Brudno JN, et al. ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells. Biol Blood Marrow Transpl. 2019;25:625–38. https://doi.org/10.1016/j.bbmt.2018.12.758.
Khwaja A. KDIGO clinical practice guidelines for acute kidney injury. Nephron Clin Pr. 2012;120:c179–84. https://doi.org/10.1159/000339789.
Ansari R, Caimi P, Zhengyi C, Rashidi A. Renal outcomes after chimeric antigen receptor T-cell (CAR-T) therapy: a single center perspective. Nephrol Dial Transpl. 2022. https://doi.org/10.1093/ndt/gfac048.
Ellis MJ, Parikh CR, Inrig JK, Kanbay M, Patel UD. Chronic kidney disease after hematopoietic cell transplantation: a systematic review. Am J Transpl. 2008;8:2378–90. https://doi.org/10.1111/j.1600-6143.2008.02408.x.
This cohort includes 114 patients that were previously reported in studies of AKI after CAR-T (PMID: 33098925, 31973908).
MES is supported by the National Institutes of Health award R01 DK130839, K23DK117014, and the Claflin Distinguished Scholars award. The content is the responsibility of the authors alone and does not necessarily reflect the views or policies of the Department of Health and Human Services, nor does mention of trade names, commercial products, or organizations imply endorsement by the U.S. Government. These organizations were not involved in study design, analysis, interpretation, or manuscript creation.
PH, IS, DM, DH, HS, ML, TO, and MES have nothing to declare. MF is a consultant for Novartis, Kite/Gilead, BMS, Iovance, JnJ/Legend, and Arcellx. SG receives research funding from BTG International, GE Healthcare and NIH NIDDK K23DKDK125672.
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Supplemental Figure 2. Comparison of acute kidney injury rates at 15, 30, and 90 days among patients receiving autologous hematopoietic stem cell transplant or chimeric antigen receptor T cell therapy
Supplemental Table 2. Predictors of AKI among patients receiving autologous hematopoietic stem cell transplant or chimeric antigen receptor T cell therapy
Supplemental Table 3. Predictors of chronic kidney function decline among patients receiving autologous hematopoietic stem cell transplant or chimeric antigen receptor T cell therapy
Supplemental Table 4: Predictors of acute kidney injury among patients receiving chimeric antigen receptor T cell therapy
Supplemental Table 5. Predictors of chronic kidney function decline among patients receiving chimeric antigen receptor T cell therapy who survived a year.
About this article
Cite this article
Hanna, P., Strohbehn, I., Moreno, D. et al. Comparison of short- and long-term adverse kidney outcomes after chimeric antigen receptor T cell therapy and autologous hematopoietic stem cell transplant for diffuse large B cell lymphoma. Bone Marrow Transplant 57, 1623–1625 (2022). https://doi.org/10.1038/s41409-022-01767-7